The Nuances of Biomarker Implementation in a Clinical Trial: A Regulatory Perspective
Time: 12:45 pm
day: Day Two Track C
Details:
- Define the intended use of a clinical trial assay (CTA) versus a CDx-ready assay
- Compare implementation of biomarker strategy in US and EU
- Understand implications of study design on regulatory requirements US v EU
